Skip to main content
Triangle logo TriangleGet started

Sonesitatug Vedotin (NCT07069712)

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma: a one-minute explainerNCT070697121 min

Sonesitatug Vedotin trial for Gastroesophageal Adenocarcinoma (NCT07069712). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, locally advanced, resectable gastric, gastroesophageal-junction or esophageal adenocarcinoma, without distant spread. Some groups require CLDN18.2 or HER2 positivity.

The idea: combine treatment before and after surgery. Everyone receives rilvegostomig, which blocks PD-1 and TIGIT immune checkpoints. Marker-selected groups add sonesitatug vedotin or trastuzumab deruxtecan with fluoropyrimidine chemotherapy; another group receives FLOT chemotherapy. Later postoperative drugs differ by group. Researchers assess safety and whether viable cancer remains in surgical tissue.

This phase 2 study plans 100 patients. AstraZeneca sponsors five recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.